| Although bevacizumab was not non-inferior to ranibizumab and aflibercept in LEAVO, the three interventions generate similar quality-adjusted life-years. |
| Bevacizumab is always the most cost-effective intervention at £20,000–£30,000 per quality-adjusted life-year. |
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.